Zanamivir is a dry out natural powder for inhalation that will require manual dexterity to assemble and cannot be used in children under seven years of age. relevant journals and abstract books of conference proceedings. Most recent search: 02 November 2015. Selection criteria Randomised controlled trials and quasi\randomised controlled trials comparing neuraminidase inhibitors with placebo or other antiviral drugs. Data collection and analysis Two review authors had planned to independently screen studies, extract data and assess risk of bias using standard LTI-291 Cochrane methodologies. No studies were identified for inclusion. Main results No relevant studies were retrieved after a comprehensive search of the literature. Authors’ conclusions We were unable to identify any randomised controlled studies or quasi\randomised controlled studies on the efficacy of neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. The absence of high level evidence for the effectiveness of these interventions emphasises the need for well\designed, adequately powered, randomised controlled clinical studies. Plain language summary Antiviral treatment for influenza infection in people with cystic fibrosis Review question We looked for evidence for the use of antiviral treatment against influenza infection in people with cystic fibrosis. Background Cystic fibrosis is a genetic, life\threatening disorder which affects many organs in the body. and people with cystic fibrosis have a higher risk of chronic lung disease. Influenza can worsen the course of the disease in cystic fibrosis by increasing the risk of pneumonia and secondary respiratory complications. During a pandemic (an epidemic occurring worldwide, or over a very wide area, crossing international boundaries and usually affecting a large number of people), flu symptoms may be more severe and complications more frequent. Severe cases of pandemic flu have occurred in people with underlying chronic conditions including people with cystic fibrosis. Although there is no evidence that people with cystic fibrosis are more likely to contract this infection than healthy people, the impact for them could be greater and the outcome worse as the lower airways are more often affected. Antiviral agents are important in managing influenza and include the neuraminidase inhibitors zanamivir and oseltamivir. These drugs can limit the infection and prevent the spread of the virus. Search date The evidence is current to: 02 November 2015. Study characteristics We did not find any studies looking at the use of neuraminidase inhibitors for influenza in people with cystic fibrosis. Key results Limited data from previous studies have shown that these drugs can be effective in healthy people and may be useful in high\risk populations if used rationally. However, we are not able to answer the question of the safety and effectiveness of neuraminidase inhibitors for treating influenza in people with cystic fibrosis. Background Neuraminidase inhibitors (NIs) are thought to help reduce the symptoms of influenza in adults and children (Jefferson 2006; Matheson 2007). Although the proposed influenza virus\specific mechanism of action by NIs and worldwide usage and stockpiling of these agents to tackle pandemics have been recommended by public health agencies, it does not seem to fit the clinical evidence of effectiveness in the treatment of influenza as explored by the subsequent updates of the original Cochrane systematic review on this topic (Jefferson 2012; Jefferson 2014). Furthermore, little is known specific to the effectiveness and safety of NIs in treating influenza in people with cystic fibrosis (CF). Description of the condition Cystic fibrosis is the most common, life\threatening, recessively inherited disease of Caucasian populations, with a carrier rate of 1 1 in 25 and an incidence of 1 1 in 2500 live births (Ratjen 2003). It is a multisystem disorder caused by a?mutation?in the?gene?encoding the CF transmembrane conductance regulator?(CFTR) protein. The CFTR protein?is a chloride ion channel, important.Severe cases of pandemic flu have occurred in people with underlying chronic conditions including people with CF; though there is no?evidence of increased susceptibility to this infection in people with CF than in healthy people, the impact could be greater and the outcome worse as the lower respiratory tract is affected more often. Description of the intervention The two main measures for the treatment and prophylaxis of influenza are immunisation using influenza vaccines directly isolated from influenza A Rabbit Polyclonal to NRSN1 and B viruses and antiviral agents (Demicheli 2007). inhibitors for the treatment of influenza infection in people with cystic fibrosis. Search methods We looked the Cochrane Cystic Fibrosis and Genetic Disorders Group Tests Register comprising referrals identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Most recent search: 02 November 2015. Selection criteria Randomised controlled tests and quasi\randomised controlled trials comparing neuraminidase inhibitors with placebo or additional antiviral medicines. Data collection and analysis Two review authors had planned to independently display studies, draw out data and assess risk of bias using standard Cochrane methodologies. No studies were recognized for inclusion. Main results No relevant studies were retrieved after a comprehensive search of the literature. Authors’ conclusions We were unable to identify any randomised controlled studies or quasi\randomised controlled studies within the effectiveness of neuraminidase inhibitors for the treatment of influenza illness in people with cystic fibrosis. The absence of high level evidence for the effectiveness of these interventions emphasises the need for well\designed, properly powered, randomised controlled clinical studies. Simple language summary Antiviral treatment for influenza illness in people with cystic fibrosis Review query We looked for evidence for the use of antiviral treatment against influenza illness in people with cystic fibrosis. Background Cystic fibrosis is definitely a genetic, existence\threatening disorder which affects many organs in the body. and people with cystic fibrosis have a higher risk of chronic lung disease. Influenza can get worse the course of the disease in cystic fibrosis by increasing the risk of pneumonia and secondary respiratory complications. During a pandemic (an epidemic happening worldwide, or over a very wide area, crossing international boundaries and usually influencing a large number of people), flu symptoms may be more severe and complications more frequent. Severe instances of pandemic flu have occurred in people with underlying chronic conditions including people with cystic fibrosis. Although there is no evidence that people with cystic fibrosis are more likely to contract this illness than healthy people, the effect for them could be higher and the outcome worse as the lower airways are more often affected. Antiviral providers are important in controlling influenza and include the neuraminidase inhibitors zanamivir and oseltamivir. These medicines can limit the infection and prevent the spread of the disease. Search date The evidence is usually current to: 02 November 2015. Study characteristics We did not find any studies looking at the use of neuraminidase inhibitors for influenza in people with cystic fibrosis. Important results Limited data from previous studies have shown that these drugs can be effective in healthy people and may be useful in high\risk populations if used rationally. However, we are not able to answer the question of the security and effectiveness of neuraminidase inhibitors for treating influenza in people with cystic fibrosis. Background Neuraminidase inhibitors (NIs) are thought to help reduce the symptoms of influenza in adults and children (Jefferson 2006; Matheson 2007). Even though proposed influenza computer virus\specific mechanism of action by NIs and worldwide usage and stockpiling of these agents to tackle pandemics have been recommended by public health agencies, it does not seem to fit the clinical evidence of effectiveness in the treatment of influenza as explored by the subsequent updates of the original Cochrane systematic review on this topic (Jefferson 2012; Jefferson 2014). Furthermore, little is known specific to the effectiveness and security of NIs in treating influenza in people with cystic fibrosis (CF). Description of the condition Cystic fibrosis is the most common, life\threatening, recessively inherited disease of Caucasian populations, with a carrier rate of 1 1 in 25 and an incidence of 1 1 in 2500 live births (Ratjen 2003). It is a multisystem disorder caused by a?mutation?in the?gene?encoding the CF transmembrane conductance regulator?(CFTR) protein. The CFTR protein?is usually a chloride ion channel, important in producing sweat,?digestive?juices and?mucus. The impaired or absent function of this protein results in the production of viscous mucus within the lungs and.They will compare the evaluations and any disagreements between the review authors will be discussed and resolved. The following domains will be assessed as ‘Yes’ (i.e. prevent the spread of the computer virus. Objectives To assess the effects of neuraminidase inhibitors for the treatment of influenza contamination in people with cystic fibrosis. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising recommendations identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Most recent search: 02 November 2015. Selection criteria Randomised controlled trials and quasi\randomised controlled trials comparing neuraminidase inhibitors with placebo or other antiviral drugs. Data collection and analysis Two review authors had planned to independently screen studies, extract data and assess risk of bias using standard Cochrane methodologies. No studies were recognized LTI-291 for inclusion. Main results No relevant studies were retrieved after a comprehensive search of the literature. Authors’ conclusions We were unable to identify any randomised controlled studies or quasi\randomised controlled studies around the efficacy of neuraminidase inhibitors for the treatment of influenza contamination in people with cystic fibrosis. The absence of high level evidence for the effectiveness of these interventions emphasises the need for well\designed, properly powered, randomised controlled clinical studies. Basic language overview Antiviral treatment for influenza infections in people who have cystic fibrosis Review issue We appeared for proof for the usage of antiviral treatment against influenza infections in people who have cystic fibrosis. History Cystic fibrosis is certainly a genetic, lifestyle\intimidating disorder which impacts many organs in the torso. and folks with cystic fibrosis possess a higher threat of chronic lung disease. Influenza can aggravate the span of the condition in cystic fibrosis by raising the chance of pneumonia and supplementary respiratory complications. Throughout a pandemic (an epidemic taking place worldwide, or higher an extremely wide region, crossing international limitations and usually impacting a lot of people), flu symptoms could be more serious and complications even more frequent. Severe situations of pandemic flu possess occurred in people who have underlying chronic circumstances including people who have cystic fibrosis. Although there is absolutely no proof that folks with cystic fibrosis will contract this infections than healthful people, the influence for them could possibly be better and the results worse as the low airways are more regularly affected. Antiviral agencies are essential in handling influenza you need to include the neuraminidase inhibitors zanamivir and oseltamivir. These medications can limit chlamydia and stop the spread from the pathogen. Search date The data is certainly current to: 02 November 2015. Research characteristics We didn’t find any research looking at the usage of neuraminidase inhibitors for influenza in people who have cystic fibrosis. Crucial outcomes Limited data from prior studies show that these medications could be effective in healthful people and could end up being useful in high\risk populations if utilized rationally. Nevertheless, we cannot answer fully the question from the protection and efficiency of neuraminidase inhibitors for dealing with influenza in people who have cystic fibrosis. History Neuraminidase inhibitors (NIs) are believed in reducing the symptoms of influenza in adults and kids (Jefferson 2006; Matheson 2007). Even though the proposed influenza pathogen\specific system of actions by NIs and world-wide use and stockpiling of the agents to deal with pandemics have already been suggested by public wellness agencies, it generally does not seem to suit the clinical proof efficiency in the treating influenza as explored by the next updates of the initial Cochrane organized review upon this subject (Jefferson 2012; Jefferson 2014). Furthermore, small is known specific to the effectiveness and safety of NIs in treating influenza in.These drugs can limit the infection and prevent the spread of the virus. Search date The evidence is current to: 02 November 2015. Study characteristics We did not find any studies looking at the use of neuraminidase inhibitors for influenza in people with cystic fibrosis. Key results Limited data from previous studies have shown that these drugs can be effective in healthy people and may be useful in high\risk populations if used rationally. limit the infection and prevent the spread of the virus. Objectives To assess the effects of neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Most recent search: 02 November 2015. Selection criteria Randomised controlled trials and quasi\randomised controlled trials comparing neuraminidase inhibitors with placebo or other antiviral drugs. Data collection and analysis Two review authors had planned to independently screen studies, extract data and assess risk of bias using standard Cochrane methodologies. No studies were identified for inclusion. Main results No relevant studies were retrieved after a comprehensive search of the literature. Authors’ conclusions We were unable to identify any randomised controlled studies or quasi\randomised controlled studies on the efficacy of neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. The absence of high level evidence for the effectiveness of these interventions emphasises the need for well\designed, adequately powered, randomised controlled clinical studies. Plain language summary Antiviral treatment for influenza infection in people with cystic fibrosis Review question We looked for evidence for the use of antiviral treatment against influenza infection in people with cystic fibrosis. Background Cystic fibrosis is a genetic, life\threatening disorder which affects many organs in the body. and people with cystic fibrosis have a higher risk of chronic lung disease. Influenza can worsen the course of the disease in cystic fibrosis by increasing the risk of pneumonia and secondary respiratory complications. During a pandemic (an epidemic occurring worldwide, or over a very wide area, crossing international boundaries and usually affecting a large number of people), flu symptoms may be more severe and complications more frequent. Severe cases of pandemic flu have occurred in people with underlying chronic conditions including people with cystic fibrosis. Although there is no evidence that people with cystic fibrosis will contract this an infection than healthful people, the influence for them could possibly be better and the results worse as the low airways are more regularly affected. Antiviral realtors are essential in handling influenza you need to include the neuraminidase inhibitors zanamivir and oseltamivir. These medications can limit chlamydia and stop the spread from the trojan. Search date The data is normally current to: 02 November 2015. Research characteristics We didn’t find any research looking at the usage of neuraminidase inhibitors for influenza in people who have cystic fibrosis. Essential outcomes Limited data from prior studies show that these medications could be effective in healthful people and could end up being useful in high\risk populations LTI-291 if utilized rationally. Nevertheless, we cannot answer fully the question of the basic safety and efficiency of neuraminidase inhibitors for dealing with influenza in people who have cystic fibrosis. History Neuraminidase inhibitors (NIs) are believed in reducing the symptoms of influenza in adults and kids (Jefferson 2006; Matheson 2007). However the proposed influenza trojan\specific system of actions by NIs and world-wide use and stockpiling of the agents to deal with pandemics have already been suggested by public wellness agencies, it generally does not seem to suit the clinical proof efficiency in the treating influenza as explored by the next updates of the initial Cochrane organized review upon this subject (Jefferson 2012; Jefferson 2014). Furthermore, small is known particular to the efficiency and basic safety of NIs in dealing with influenza in people who have cystic fibrosis (CF). Explanation of the problem Cystic fibrosis may be the most common, lifestyle\intimidating, recessively inherited disease of Caucasian populations, using a carrier price of just one 1 in 25 and an occurrence of just one 1 in 2500 live births (Ratjen 2003). It really is a multisystem disorder the effect of a?mutation?in the?gene?encoding the CF transmembrane conductance regulator?(CFTR) protein. The CFTR proteins?is normally a chloride ion route, important in producing sweating,?digestive?juices and?mucus. The impaired or absent function of the proteins leads to the creation of viscous mucus inside the lungs and a host that is vunerable to persistent airway blockage and pulmonary colonization by pathogenic bacterias. A lot of the morbidity and a lot more than 90% from the mortality of CF relates to.Every one of the stakeholders should acquire whole usage of clinical data reviews and individual research leads to avoid publication bias and selective reporting afterwards” (Michiels 2013). What’s new
8 Apr 2021Review declared as stableDue to too little research in this field the Editorial Plank from the Cystic Fibrosis and Genetic Disorders Review Group are determined to no more update this review. History Protocol initial published: Issue 4, 2009
Review first published: Issue 3, 2010
15 February 2016New search has been performedA search of the Cochrane Cystic Fibrosis and Genetic Disorders Review Group did not identify any new references potentially eligible for inclusion in this review.15 February 2016New citation required but conclusions have not changedSince no new studies have been included in this updated review, our conclusions remain the same.10 February 2014New search has been performedA search of the Cystic Fibrosis & Genetic Disorders Group’s Cystic Fibrosis Trials Register did not identify any potentially eligible studies for inclusion in this review.10 February 2014New citation required but conclusions have not changedNo new studies were included in this update of the review, therefore our conclusions remain the same.
Jai Shanthini Singaram has stepped down from the author team for this update.26 October 2011New search has been performedA search of the Group’s Cystic Fibrosis Trials Register did not identify any new references potentially eligible for inclusion in the update of this review.26 April 2010AmendedContact details updated. Acknowledgements The authors would like to thank Nikki Jahnke of the Cochrane Cystic Fibrosis and Genetic Disorders Group for her support throughout this protocol and the peer reviewers (Dr Callum Semple (UK), Dr Jayesh Bhatt (UK), Mr Stephen Milan (UK), Dr Kerry Dwan UK), Dr Karen Welch (UK)) for their useful comments which were a great help in conducting this systematic review. Notes Stable (no update expected for reasons given in ‘What’s new’) Differences between protocol and review In line with the WHO recommendations of antiviral treatment in the ongoing H1N1 pandemic which recommends initial treatment decisions to be based on clinical assessment and knowledge about the presence of the virus in the community without waiting for laboratory confirmation (WHO 2009), the definition of Types of participants has been changed in the review to also include the people with CF with only clinical diagnosis of influenza (without laboratory confirmation) . There is an additional primary outcome listed in the review compared to the protocol ‘Time to alleviation of constitutional symptoms’. proceedings. Most recent search: 02 November 2015. Selection criteria Randomised controlled trials and quasi\randomised controlled trials comparing neuraminidase inhibitors with placebo or other antiviral drugs. Data collection and analysis Two review authors had planned to independently screen studies, extract data and assess risk of bias using standard Cochrane methodologies. No studies were identified for inclusion. Main results No relevant studies were retrieved after a comprehensive search of the literature. Authors’ conclusions We were unable to identify any randomised controlled studies or quasi\randomised controlled studies on the efficacy of neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. The absence of high level evidence for the effectiveness of these interventions emphasises the need for well\designed, adequately powered, randomised controlled clinical studies. Plain language summary Antiviral treatment for influenza infection in people with cystic fibrosis Review question We looked for evidence for the use of antiviral treatment against influenza infection in people with cystic fibrosis. Background Cystic fibrosis is a genetic, life\threatening disorder which affects many organs in the body. and people with cystic fibrosis have a higher risk of chronic lung disease. Influenza can worsen the course of the disease in cystic fibrosis by increasing the risk of pneumonia and secondary respiratory complications. During a pandemic (an epidemic occurring worldwide, or over a very wide area, crossing international boundaries and usually affecting a large number of people), flu symptoms may be more severe and complications more frequent. Severe cases of pandemic flu have occurred in people with underlying chronic conditions including people with cystic fibrosis. Although there is no evidence that people with cystic fibrosis are more likely to contract this infection than healthy people, the impact for them could be greater and the outcome worse as the lower airways are more often affected. Antiviral agents are important in managing influenza and include the neuraminidase inhibitors zanamivir and oseltamivir. These drugs can limit the infection and prevent the spread of the virus. Search date The evidence is current to: 02 November 2015. Study characteristics We did not find any studies looking at the use of neuraminidase inhibitors for influenza in people with cystic fibrosis. Key results Limited data from previous studies have shown that these drugs can be effective in healthy people and may be useful in high\risk populations if used rationally. However, we are not able to answer the question of the safety and effectiveness of neuraminidase inhibitors for treating influenza in people with cystic fibrosis. Background Neuraminidase inhibitors LTI-291 (NIs) are thought to help reduce the symptoms of influenza in adults and children (Jefferson 2006; Matheson 2007). Although the proposed influenza virus\specific mechanism of action by NIs and worldwide usage and stockpiling of these agents to tackle pandemics have been recommended by public health agencies, it does not seem to fit the clinical evidence of effectiveness in the treatment of influenza as explored by the subsequent updates of the original Cochrane systematic review on this topic (Jefferson 2012; Jefferson 2014). Furthermore, little is known specific to the performance and security of NIs in treating influenza in people with cystic fibrosis (CF). Description of the condition Cystic fibrosis is the most common, existence\threatening, recessively inherited disease of Caucasian populations, having a carrier rate of 1 1 in 25 and an incidence of 1 1 in 2500 live births (Ratjen 2003). It is a multisystem disorder caused by a?mutation?in the?gene?encoding the CF transmembrane conductance regulator?(CFTR) protein. The CFTR protein?is definitely a chloride ion channel, important in producing perspire,?digestive?juices and?mucus. The impaired or absent function of this protein results in the production of viscous mucus within the lungs and an environment that is susceptible to chronic airway obstruction and pulmonary colonization by pathogenic bacteria. Most of the morbidity and more than 90% of the mortality of CF is related to chronic pulmonary sepsis.